ProMIS Neurosciences

ProMIS Neurosciences ROE

Delisted

The Return on Equity (ROE) of ProMIS Neurosciences (PMN.TO) as of Oct 20, 2026 is 1,340.13 %. In the previous year, Return on Equity (ROE) was -172.97 % — a change of -874.79% (higher).

ROE

1,340.13 %

YoY

-874.79%

Last updated:

In 2022, ProMIS Neurosciences's return on equity (ROE) was 1,340.13 %, a -874.79% increase from the -172.97 % ROE in the previous year.

The ProMIS Neurosciences ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2015
-353.33 CAD
Jan 1, 2016
-4,928.57 CAD
Jan 1, 2017
-393.46 CAD
Jan 1, 2018
-876.72 CAD
Jan 1, 2019
-1,850.00 CAD
Jan 1, 2020
554.90 CAD
Jan 1, 2021
-172.97 CAD
Jan 1, 2022
1,340.13 CAD
The ProMIS Neurosciences ROE history
YEARROEYoY
1,340.13 %-874.79%
-172.97 %-131.17%
554.90 %-129.99%
-1,850.00 %+111.01%
-876.72 %+122.82%
-393.46 %-92.02%
-4,928.57 %+1,294.88%
-353.33 %-133.02%
1,070.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

ProMIS Neurosciences Stock analysis

What does ProMIS Neurosciences do? ProMIS Neurosciences Inc is a biopharmaceutical company based in Canada that specializes in the discovery and development of novel therapeutics for neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. The company was founded in 2004 and has been listed on the Toronto Stock Exchange since 2015. The goal of ProMIS is to develop highly specific therapeutics that specifically target the cellular causes of neurodegenerative diseases and can therefore stop or even reverse the progression of the disease. The company utilizes its proprietary platform technology to identify the unique epitopes on the pathological proteins that are specific to neurodegenerative diseases. ProMIS' business model is based on partnerships with large pharmaceutical companies that are searching for new therapeutics for neurodegenerative diseases. ProMIS works closely with these partners to develop customized therapeutics tailored to each partner's specific needs. The company licenses its technology and products to its partners and receives license and milestone payments when certain development or sales goals are achieved. ProMIS has different divisions to focus on various neurodegenerative diseases, with a focus on Alzheimer's, Parkinson's, and ALS. ProMIS has a comprehensive research and development infrastructure that focuses on the identification, characterization, and optimization of therapeutic antibodies and biomarkers. In terms of products, ProMIS has developed various antibodies that specifically target pathological proteins such as Aß and Tau in Alzheimer's and alpha-synuclein in Parkinson's. These antibodies can selectively recognize and bind to these pathological proteins, allowing them to be broken down and removed from the body. ProMIS works closely with its partners to test these antibodies in clinical trials and eventually bring them to market. In addition to its antibody products, ProMIS has also developed neuromethods that allow researchers to characterize and quantify the functions of proteins in brain cells and in vivo. These methods can be used to test and optimize the effects of antibodies and other therapeutics, making them an important part of ProMIS' development infrastructure. Overall, ProMIS Neurosciences Inc is an innovative biopharmaceutical company that focuses on the development of highly specific therapeutics for neurodegenerative diseases. The company has a comprehensive infrastructure and technology platform that allows it to develop customized products for its partners. With its antibodies and neuromethods, ProMIS has the potential to make a breakthrough in the treatment of neurodegenerative diseases and improve the lives of millions of patients. ProMIS Neurosciences is one of the most popular companies on Eulerpool.

ROE Details

Decoding ProMIS Neurosciences's Return on Equity (ROE)

ProMIS Neurosciences's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing ProMIS Neurosciences's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

ProMIS Neurosciences's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in ProMIS Neurosciences’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about ProMIS Neurosciences stock

Return on Equity (ROE) of ProMIS Neurosciences is 1,340.13 % in 2022.

Return on Equity (ROE) of ProMIS Neurosciences changed from -172.97 % to 1,340.13 %, representing a -874.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) ProMIS Neurosciences since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s ProMIS Neurosciences with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — ProMIS Neurosciences

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — ProMIS Neurosciences